凯盛新材(301069) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥201,347,043.80, a decrease of 14.63% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥1,764,529.79, representing a decline of 105.77% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was -¥6,231,663.35, down 121.02% from the previous year[3]. - Total operating revenue for Q3 2024 was CNY 695,989,904.34, a decrease of 4.4% compared to CNY 727,822,965.45 in Q3 2023[15]. - Net profit for Q3 2024 was CNY 51,981,530.84, down 61.0% from CNY 133,333,903.69 in Q3 2023[16]. - The net profit attributable to the parent company for Q3 2024 is CNY 52,244,600.58, a decrease from CNY 133,631,894.37 in the same period last year, representing a decline of approximately 61.1%[17]. - The total comprehensive income for Q3 2024 is CNY 51,981,530.84, down from CNY 133,333,903.69 in the previous year, indicating a decrease of about 61.0%[17]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥46,091,360.16, an increase of 192.39% compared to the same period last year[3]. - Cash flow from operating activities for Q3 2024 is CNY 46,091,360.16, a significant improvement compared to a net cash outflow of CNY 49,889,728.33 in Q3 2023[18]. - The company reported a total cash inflow from operating activities of CNY 515,330,298.06 in Q3 2024, compared to CNY 384,100,990.16 in the previous year, reflecting an increase of approximately 34.2%[18]. - The cash outflow for purchasing goods and services in Q3 2024 is CNY 321,773,364.35, up from CNY 252,249,258.95 in Q3 2023, indicating an increase of about 27.5%[18]. - The net cash flow from financing activities for Q3 2024 is -CNY 78,258,511.02, compared to -CNY 63,096,000.00 in the same period last year, indicating a worsening of cash flow from financing[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,462,878,671.11, a decrease of 0.81% from the end of the previous year[3]. - Total liabilities decreased to CNY 805,463,898.43 from CNY 814,013,531.73, a reduction of 1.7%[15]. - The total assets amounted to CNY 2,462,878,671.11, slightly down from CNY 2,482,942,697.11, reflecting a 0.8% decrease[15]. - The company's equity attributable to shareholders was CNY 1,654,069,625.39, down from CNY 1,665,320,948.35, a decline of 0.4%[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,763[8]. - The largest shareholder, Huabang Life Health, holds 44.51% of the shares, totaling 187,216,000 shares[8]. - The top ten shareholders account for a significant portion of the company's equity, with the top shareholder alone holding over 44%[8]. - The company has not reported any changes in the number of preferred shareholders or their holdings[11]. - The report indicates that there are no known relationships among the top shareholders that would classify them as acting in concert[10]. Investment and Expenses - The company's financial expenses increased by ¥21,362,600, representing a rise of 693.93% year-on-year, mainly due to new convertible bond interest expenses[6]. - The investment income increased by ¥5,080,800, a growth of 130.53% year-on-year, attributed to the increased scale of financial products held[6]. - Total operating costs increased to CNY 653,215,521.28, up 12.9% from CNY 578,530,132.45 in the previous year[16]. - Research and development expenses were CNY 39,202,196.52, slightly up from CNY 38,118,847.77, indicating a focus on innovation[16]. - The company reported a financial expense of CNY 18,284,070.98, compared to a financial income of CNY 3,078,488.53 in the previous year, indicating a shift in financial performance[16]. Cash and Financial Assets - The company's cash and cash equivalents decreased from 849,328,531.65 CNY at the beginning of the period to 493,624,473.04 CNY at the end[13]. - Trading financial assets increased significantly from 92,934,251.99 CNY to 421,818,894.62 CNY during the same period[13]. - The company's cash and cash equivalents at the end of Q3 2024 amount to CNY 450,414,797.25, down from CNY 254,209,285.82 at the end of Q3 2023[19]. - The company's cash flow from investing activities decreased by ¥461,485,300, primarily due to increased investment in financial products[7].